INTRODUCTION
============

Primary Sjögren\'s syndrome (pSS) is a chronic autoimmune inflammatory disease primarily targeting the exocrine gland and is characterized by the presence of organ specific or non-specific auto-antibodies and focal lymphocytic infiltration in the exocrine glands \[[@b1-kjim-2017-158]\]. Although the major clinical manifestation of pSS is sicca symptoms, 20% to 40% of the patients develop wide spectrum of extra-glandular involvement \[[@b2-kjim-2017-158]\]. Such heterogeneous clinical features of pSS can be divided into two groups: benign subjective manifestations, such as dry eye and mouth, myalgia, or fatigue, and systemic manifestations, including vasculitis, renal involvement, and peripheral or central nerve involvement \[[@b2-kjim-2017-158]\].

The European League Against Rheumatism (EULAR) SS Patient Reported Index (ESSPRI) and the EULAR SS Disease Activity Index (ESSDAI) are the tools used to assess the disease activity of SS and are considered the gold-standard outcome measures \[[@b3-kjim-2017-158]\]. ESSPRI is used to evaluate the subjective perception of the most important and frequent symptoms, and ESSDAI measures 12 organ-specific domains based on the severity of extra-glandular involvement \[[@b4-kjim-2017-158],[@b5-kjim-2017-158]\]. The ESSPRI and ESSDAI, which are not correlated, reflect two different facets (benign sicca symptoms and severe systemic manifestations) of the clinical disease \[[@b2-kjim-2017-158]\].

Increased sleep disturbance has been reported in patients with several rheumatic diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus \[[@b6-kjim-2017-158],[@b7-kjim-2017-158]\]. Sleep disturbance could result from disease-associated inflammatory symptoms and depression \[[@b8-kjim-2017-158]\]. Sleep disturbance could affect the immune and inflammatory response and may increase the risk of developing an autoimmune disease \[[@b9-kjim-2017-158]\]. As previously reported, the prevalence of sleep disturbance in patients with pSS was significantly higher compared to controls or to patients with RA \[[@b10-kjim-2017-158]-[@b12-kjim-2017-158]\], and poor sleep quality in pSS was associated with pain, fatigue, and depression \[[@b10-kjim-2017-158],[@b13-kjim-2017-158],[@b14-kjim-2017-158]\]. These results suggest an association between sleep disturbance and the disease activity of pSS. However, no studies on their association in patients with pSS have been published. Thus, we studied the prevalence of poor sleepers and investigated the association between sleep quality and the disease activity indices in Korean patients with pSS.

METHODS
=======

Study subjects
--------------

We consecutively enrolled 115 patients with pSS (112 females and three males; mean age, 53.0 ± 1.2 years), who had been followed in our Rheumatology Clinic from January 2015 to April 2016. All patients satisfied the classification criteria of the American European Consensus Group for pSS \[[@b15-kjim-2017-158]\]. The demographic, clinical, and laboratory variables of the patients, including medications prescribed over 3 months, were collected. At enrollment, the ESSPRI, EULAR sicca score (ESS), and ESSDAI were calculated as previously defined \[[@b4-kjim-2017-158],[@b5-kjim-2017-158]\]. A moderately active disease was defined as an ESSDAI ≥ 5 and an unsatisfactory symptom state was defined as an ESSPRI ≥ 5 \[[@b16-kjim-2017-158]\]. This study was approved by our Institutional Review Board (IRB No. B-0506/021-004) and written informed consent was obtained from all participants.

The questionnaires
------------------

The patients completed the Korean version of the Pittsburgh Sleep Quality index (PSQI) \[[@b17-kjim-2017-158]\]. The PSQI is a self-reported questionnaire to discriminate between "good" and "poor" sleepers and widely used for evaluating sleep quality because of its broad range in measuring several aspects of sleep quality and combining results into a global score \[[@b18-kjim-2017-158]\]. Based on the published literature, a cut-off total score of 8.5 was used to identify Korean poor sleepers in this study \[[@b17-kjim-2017-158]\]. All patients answered the Korean version of questionnaires on quality of life (EuroQol 5-dimensional questionnaire \[EQ-5D\]), fatigue (fatigue severity score \[FSS\]), and depression (Beck Depression Inventory \[BDI\] II) \[[@b19-kjim-2017-158]-[@b21-kjim-2017-158]\]. Depression was defined as a BDI-II score ≥ 14, and we used ≥ 4.0 as the cut-off value for the FSS to define the presence of fatigue as suggested by Valko et al. \[[@b22-kjim-2017-158]\]. Moreover, to evaluate the symptom severity, we used the xerostomia inventory (XI), the Ocular Surface Disease Index (OSDI), and a 10-cm, visual analogue scale (VAS) for overall oral dryness, nocturnal oral dryness, overall eye dryness, eyeball pain, arthralgia, myalgia, and anxiety \[[@b23-kjim-2017-158],[@b24-kjim-2017-158]\]. We also measured the patient global assessment (PGA) using a VAS.

Statistical analysis
--------------------

Continuous values were expressed as the median (interquartile range \[IQR\]) because a normal distribution was not observed in most variables. The Mann-Whitney test or Kruskal-Wallis test was used to compare the continuous variables. We performed the Jonckheere-Terpstra test to check for trends and used the chi-square or Fisher exact test to compare categorical variables. Spearman\'s rank correlation coefficient was calculated by bivariate correlation. To find the independent factors of poor sleep quality or the unsatisfactory symptom state (ESSPRI ≥ 5), we performed a stepwise multivariate logistic regression analysis, using a forward selection method. All variables with *p* \< 0.1 in the univariate analyses were included and all continuous variables except age were converted into categorical variables in the multivariate analysis. Statistical analysis was performed with SPSS version 22 (IBM Co., Armonk, NY, USA). A *p* \< 0.05 was considered significant.

RESULTS
=======

Patient characteristics and the prevalence of poor sleep quality in pSS patients
--------------------------------------------------------------------------------

The characteristics of the patients with pSS are summarized in [Table 1](#t1-kjim-2017-158){ref-type="table"}. Sixty-two patients (53.9%) had an unsatisfactory symptom state and 19 (16.5%) had a moderate-to-high disease activity (ESSDAI ≥ 5). The median total PSQI score was 8.0 (IQR, 5.0 to 12.0; mean ± standard deviation, 8.92 ± 4.62) and the prevalence of poor sleepers (PSQI \> 8.5) was 46.1%.

When patients with pSS were classified into poor and good sleepers according to their PSQI scores, the poor sleepers were significantly older (median age, 59 years vs. 52 years, *p* \< 0.05). The prevalence for the fulfilled classification criteria at the time of diagnosis was not different, except for a minor salivary gland biopsy with a focus score ≥ 1 (100% in poor sleepers vs. 68.2% in good sleepers, *p* \< 0.001). Poor sleepers were more likely to take pilocarpine (64.2% vs. 40.3%, *p* \< 0.05) and hypnotics (13.2% vs. 1.6%, *p* \< 0.05). However, the frequency of comorbidities including fibromyalgia (n = 7) and restless leg syndrome (n = 7) was comparable between the two subgroups.

At enrollment, poor sleepers exhibited a significantly lower prevalence of leukopenia (17.0% vs. 48.4%, *p* \< 0.001) and neutropenia (5.7% vs. 22.6%, *p* \< 0.05). Concordantly ESSDAI was significantly lower in poor sleeper than in good sleepers (median, 1 vs. 2.5, *p* \< 0.05) although the proportion of patients with moderate-to-high disease activity was not different between the two subgroups.

Comparison of ESSPRI and other patient-reported indices between good and poor sleepers
--------------------------------------------------------------------------------------

Concerning self-reported symptom severity, poor sleepers had a significantly higher VAS level of overall eye dryness (median, 60 vs. 40, *p* \< 0.05), arthralgia (40 vs. 10, *p* \< 0.01), anxiety (10 vs. 2.5, *p* \< 0.05), and overall PGA (49 vs. 10, *p* \< 0.001) compared to the good sleepers ([Table 2](#t2-kjim-2017-158){ref-type="table"}). The XI, OSDI, and VAS scores for overall oral dryness, night oral dryness, eyeball pain, and myalgia tended to be higher in poor sleeper; however, the difference was not significant. Additionally, the EQ-5D score was significantly lower (median, 0.690 vs. 0.785, *p* \< 0.001) and the ESS (6.0 vs. 5.0, *p* \< 0.05), FSS (41 vs. 23, *p* \< 0.001), and BDI-II (15 vs. 7.5, *p* \< 1 × 10^--4^) scores were significantly higher in poor sleepers than in good sleepers ([Table 2](#t2-kjim-2017-158){ref-type="table"}). Thirty of 44 pSS patients (68.2%) with depression reported poor sleep quality, whereas 23 of 71 patients (32.4%) without depression were poor sleepers (*p* \< 0.001). Poor sleepers showed a significantly higher ESSPRI compared to good sleepers (median, 6.0 vs. 4.2, *p* \< 0.001), and the proportion of subjects with a patient-unacceptable symptom state was 61.3% in poor sleepers and 38.7% in good sleepers (*p* \< 0.001).

Correlations between sleep quality and clinical variables
---------------------------------------------------------

From the bivariate correlation analyses, age and EQ-5D were significantly positively and negatively associated with the PSQI scores, respectively ([Table 3](#t3-kjim-2017-158){ref-type="table"}). The PSQI score was a significant determinant of the highest EQ-5D quartile in the multivariate analysis (*p* = 0.013; odds ratio, 1.165; 95% confidence interval, 1.032 to 1.315).

The XI, OSDI, and VAS scores for sicca symptoms, eyeball pain, arthralgia, myalgia, and anxiety were significantly associated with the PSQI scores in all patients with pSS (all *p* \< 0.05) ([Table 3](#t3-kjim-2017-158){ref-type="table"}). The PSQI scores were significantly positively correlated with the BDI-II and FSS scores (all *p* \< 1 × 10^--5^) and the white blood cell (WBC) or absolute neutrophil counts (ANC), but negatively correlated with the total immunoglobulin G (IgG) levels (all *p* \< 0.05) ([Table 3](#t3-kjim-2017-158){ref-type="table"}). Moreover, the PSQI was positively associated with the ESSPRI (*p* \< 1.0 × 10^--5^) and negatively associated with the ESSDAI (*p* = 0.005).

When the patients were stratified according to PSQI quartiles, the distribution of ESS, arthralgia VAS, FSS, WBC counts or ANC, ESSPRI and ESSDAI was significantly different across the quartiles (all *p* \< 0.05) ([Figs. 1](#f1-kjim-2017-158){ref-type="fig"} and [2](#f2-kjim-2017-158){ref-type="fig"}). In addition, a significant trend was found across the PSQI quartiles for ESS, arthralgia VAS, FSS, WBC counts, ANC, and serum IgG (all *p* \< 0.05) ([Figs. 1](#f1-kjim-2017-158){ref-type="fig"} and [2](#f2-kjim-2017-158){ref-type="fig"}). Finally, significant increasing trends of ESSPRI (*p* \< 1.0 × 10^--5^) or decreasing trends of ESSDAI (*p* \< 0.01) were observed across the increasing quartiles. However, a significant trend for the ESSDAI was not observed when patients were stratified according to quartiles of FSS, BDI-II, or other patient symptom severity levels.

Independent association between poor sleep quality and ESSPRI in pSS patients
-----------------------------------------------------------------------------

Because the variables were mutually correlated, a multivariate analysis was performed adjusting for age to identify factors associated with poor sleep quality in patients with pSS. All continuous variables except for age were entered as dichotomous variables based on the highest or lowest quartile or clinically relevant cut-points (ESSPRI ≥ 5, ESSDAI ≥ 5, FSS ≥ 4, BDI-II ≥ 14, leukopenia \[WBC \< 4,000/μL\], or neutropenia \[ANC \< 1,500/μL\]) \[[@b16-kjim-2017-158],[@b17-kjim-2017-158],[@b20-kjim-2017-158]-[@b22-kjim-2017-158]\].

Poor sleep quality was significantly independently associated with depression, leukopenia, and pilocarpine usage in all patients with pSS ([Table 4](#t4-kjim-2017-158){ref-type="table"}). Although poor sleep quality is strongly associated with depression, about a third of the pSS patients without depression had poor sleep quality in this study. Therefore, multivariate analysis was repeated after dividing the study subjects according to a BDI-II ≥ 14. Poor sleep quality was significantly associated with the unsatisfactory symptom state (ESSPRI ≥ 5) and ever-smoking in pSS patients without depression. Furthermore, in a multivariate analysis with the ESSPRI ≥ 5 as the dependent variable, poor sleep quality was an independent contributor to the patient-unacceptable symptom state.

Univariate analyses revealed that poor sleep quality was significantly associated with the WBC or neutrophil counts and IgG levels, and multivariate analysis showed a negative association with leukopenia. Although these variables are the components included in calculating the ESSDAI, an independent association between poor sleep quality and ESSDAI was not observed in the multivariate analysis.

DISCUSSION
==========

This study showed that 46.1% of the patients with pSS reported poor sleep quality and, even among the pSS patients without depression, 32.4% were poor sleepers. These poor sleepers had more severe glandular and extra-glandular symptoms compared to the good sleepers. Furthermore, for the first time, we found that poor sleep quality in patients with pSS was independently associated with the ESSPRI and that the ESSDAI might be underestimated in poor sleepers, because poor sleep quality could be negatively associated with the WBC or neutrophil counts and IgG levels.

Sleep impairment is common in chronic inflammatory diseases \[[@b8-kjim-2017-158]\]. However, the prevalence of sleep disturbance in patients with pSS has not been extensively studied. Nevertheless, in a previous study, 75% of 65 Israeli patients with pSS had moderate to severe sleep disturbance based on the Mini Sleep Questionnaire \[[@b10-kjim-2017-158]\]. In addition, in 40 Swedish patients with pSS, 72% complained of "too little sleep," and in 29 Italian patients with pSS, 82.8% had sleep complaints (mean PSQI score, 8.62 ± 4.58) \[[@b11-kjim-2017-158],[@b13-kjim-2017-158]\]. In contrast, Segal et al. \[[@b12-kjim-2017-158]\] reported that 37.8% of 108 American patients with pSS had self-reported sleep disorder. Such variation may be related to different assessment methods or to the different prevalence of depression in the study subjects. Moreover, previous studies have shown that the prevalence of disturbed sleep was significantly higher in patients with pSS than in patients with RA or in controls \[[@b10-kjim-2017-158],[@b11-kjim-2017-158],[@b13-kjim-2017-158]\]. Although a control group was not included in this study, the PSQI scores of the subjects were much higher than those in previous reports with Korean subjects (4.06 ± 2.08 in 133 healthy controls, 5.62 ± 4.19 in 130 RA patients, and 6.0 ± 3.6 in 2,040 subjects aged ≥ 60 years) \[[@b17-kjim-2017-158],[@b25-kjim-2017-158],[@b26-kjim-2017-158]\]. These data show that a significant portion of patients with pSS appears to have poor sleep quality to a similar extent as patients with other rheumatic diseases \[[@b8-kjim-2017-158]\].

Whether sleep alterations are the results of disease-related symptoms, including sicca symptoms, pain, and depression, or disease-related immune changes remains unclear. Severe xerostomia may disturb nocturnal sleep because the salivary flow rate decreases during sleep. It was also shown that dry mouth in patients with pSS was independently associated with sleep quality and that subjects complaining of dry mouth had a decrease in sleep quality \[[@b27-kjim-2017-158]\]. Furthermore, poor sleep is common in individuals with dry eye; sleep quality was associated the severity of dry eye \[[@b28-kjim-2017-158]\]. Sleep deprivation could reduce tear secretion and decreases the tear film break-up time \[[@b29-kjim-2017-158]\]. However, in this study, although poor sleepers had a higher ESS than that of the good sleepers, their self-reported level of oral and dry symptoms was not significantly higher, except for overall eye dryness.

We observed that poor sleepers reported a higher level of arthralgia or myalgia in this study. The severity of neuropathic pain was previously shown to be associated with poor sleep quality in patients with pSS \[[@b12-kjim-2017-158]\], but no reports on the association between musculoskeletal pain and sleep disturbance are available in patients with pSS. In contrast, an association between arthralgia and sleep disturbance has been clearly shown in RA patients \[[@b6-kjim-2017-158]\]. Sleep impairments are suggested to be a stronger and reliable predictor of pain, and sleep deprivation can increase RA-related joint pain \[[@b30-kjim-2017-158]\].

The pSS-related fatigue is a major distressing problem of patients with pSS. In this study, pSS patients with poor sleep quality showed a significantly higher level of fatigue. Because of the restorative function of sleep, it has been generally accepted that disturbed sleep is associated with fatigue. The pSS-related fatigue was previously reported to be associated with personality traits and various clinical features, including disturbed sleep \[[@b13-kjim-2017-158],[@b31-kjim-2017-158],[@b32-kjim-2017-158]\]. Furthermore, sleep deprivation can increase the expression of interleukin 6, which have play a role in both pSS-associated inflammation and fatigue \[[@b9-kjim-2017-158]\].

Depression, which is frequently accompanied by sleep disturbances, is common in pSS and strongly associated with fatigue, working disability, and widespread pain \[[@b31-kjim-2017-158],[@b32-kjim-2017-158]\]. In this study, the prevalence of depression was significantly higher in poor sleepers than in good sleepers, and depression was independently associated with poor sleep quality in the multivariate analysis. However, because a third of the pSS patients without depression were poor sleepers, poor sleep quality is not caused by depression alone. Thus, it can be deduced that poor sleep quality could be affected by the three key symptoms (sicca symptoms, pain, and fatigue) as well as by depression in patients with pSS.

ESSPRI is a disease activity index to incorporate patient-reported measures of the main pSS symptoms and was suggested to be disease-specific \[[@b33-kjim-2017-158]\]. ESSPRI, as a composite measure, could more closely reflect various aspects of sleep than a single clinical measure, considering the complex interaction between sleep and the pSS pathomechanism. In our study, the multivariate analysis showed that poor sleep quality was independently associated with the unsatisfactory symptom state (ESSPRI ≥ 5) in patients with pSS, and in those without depression, the unsatisfactory symptom state remained an independent factor for poor sleep quality. Although sialogogues or topical treatment for sicca symptoms led to the reduction of sleep disturbance, no reports on the change in sleep quality after the introduction of treatment targeting ESSPRI in patients with pSS are available, except for rituximab \[[@b34-kjim-2017-158],[@b35-kjim-2017-158]\]. Recently, the use of biologic agents and tofacitinib have been reported to improve sleep quality and disease activity in the clinical trials of RA \[[@b36-kjim-2017-158]\]. Therefore, a therapy improving the ESSPRI could improve the sleep quality in patients with pSS.

Another unique finding of this study is the lower ESSDAI level in poor sleepers than in good sleepers. Sleep restriction reportedly increases circulating the number of WBCs, neutrophils, and lymphocytes and reduces antigen-derived B cell response \[[@b37-kjim-2017-158],[@b38-kjim-2017-158]\]. These findings suggest that disturbed sleep could affect the immunopathological or laboratory features of patients with pSS. In this study, the PSQI was positively correlated with the WBC and neutrophil counts and negatively correlated with the serum IgG levels. Poor sleepers exhibited a higher WBC, as well as neutrophil and lymphocyte counts in their peripheral blood compared to good sleepers. Furthermore, the multivariate analysis showed that leukopenia was negatively associated with poor sleep quality. Eventually, the interaction between poor sleep quality and circulating neutrophils or IgG levels may reduce the score for the hematological or biological domain of the ESSDAI. Therefore, sleep quality could act as a hidden confounder in the ESSDAI estimation. However, because it failed to remain statistically significant in the multivariate analysis, the association between sleep quality and the ESSDAI needs to be tested in future studies.

This study has several limitations. First, the sample size was not large, and most subjects had a mild systemic disease activity. Thus, further studies with large sample sizes and patients with a higher ESSDAI are warranted for a definite conclusion on the association between sleep quality and disease activity indices. Second, matched controls were not enrolled. However, the total PSQI scores of our Korean patients with pSS were much higher than those of other Korean subjects in previous reports and were comparable to the results in a study by Priori et al. \[[@b13-kjim-2017-158],[@b17-kjim-2017-158],[@b25-kjim-2017-158],[@b26-kjim-2017-158]\]. Third, sleep quality was evaluated using only a self-reported questionnaire. Although polysomnography is considered the gold standard for primary sleep disorder assessment, it is labor-consuming and expensive. Moreover, considering the inconsistent association between polysomnographic findings and the PSQI, polysomnography and PSQI could evaluate different aspects of the sleep problem \[[@b39-kjim-2017-158]\]. Lastly, because sleep quality can be influenced by many internal and external factors, all confounding factors could not be excluded in this study. Nonetheless, our results suggest that the ESSPRI is not a simple combination of the three symptoms and have implications in diverse aspects of pSS including sleep quality.

In conclusion, our study showed that poor sleep quality is common in Korean patients with pSS and that an unsatisfactory symptom state is independently associated with poor sleep quality. Furthermore, poor sleep quality may lead to an underestimation of the ESSDAI in pSS. Therefore, clinicians should be aware of the possibility of poor sleep quality in pSS patients with an unsatisfactory symptom state.

KEY MESSAGE
===========

1\. Poor sleep quality is common in Korean primary Sjögren's syndrome (pSS) patients, even in those without depression.

2\. Poor sleep quality is an independent determinant of the unsatisfactory symptom state in pSS.

3\. Poor sleep quality may lead to an underestimation of physician-administered systemic activity index in pSS.
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![Distribution of patient-reported measures according to the Pittsburgh Sleep Quality Index (PSQI) quartiles. The distribution of (A) EULAR sicca score (ESS) (*p* = 0.018 by the Kruskal-Wallis test), (B) arthralgia visual analogue scale (VAS) scores (*p* = 0.013), (C) fatigue severity score (FSS) (*p* = 1.82 × 10^--4^), and (D) EULAR SS Patient Reported Index (ESSPRI) (*p* = 6.95 × 10^--5^) was significantly different among the PSQI quartiles. Additionally, a significant positive trend for the ESS, arthralgia VAS, and FSS were found across the PSQI quartiles. Eventually, a significant positive trend of the ESSPRI was observed across the PSQI quartiles. *p* values above the figures were calculated by the Jonckheere-Terpstra test. EULAR, European League Against Rheumatism; SS, Sjögren's syndrome.](kjim-2017-158f1){#f1-kjim-2017-158}

![Distribution of the hematological and immunological parameters according to the Pittsburgh Sleep Quality Index (PSQI) quartiles. The distribution of the (A) white blood cell (WBC) counts (*p* = 0.001 by the Kruskal-Wallis test) and (B) absolute neutrophil counts (ANC; *p* = 0.013) was significantly different among the PSQI quartiles, even though the difference in the (C) immunoglobulin G (IgG) levels (*p* = 0.154) was not significant. Additionally, a significant positive trend for the WBC counts or ANC and a negative trend for the IgG levels were found across the PSQI quartiles. (D) Eventually, the distribution of the EULAR SS Disease Activity Index (ESSDAI) was significantly different (*p* = 0.037) and a significant negative trend for the ESSDAI was observed across the PSQI quartiles. p values above the figures were calculated by the Jonckheere-Terpstra test. EULAR, European League Against Rheumatism; SS, Sjögren's syndrome.](kjim-2017-158f2){#f2-kjim-2017-158}

###### 

Clinical characteristics of the study subjects

  Characteristic             Total (n = 115)        Good sleeper (n = 62)   Poor sleeper (n = 53)   *p* value
  -------------------------- ---------------------- ----------------------- ----------------------- ----------------
  Female sex                 112 (97.4)             60 (96.8)               52 (98.1)               1.000
  Age, yr                    54.0 (45.0--63.0)      51.5 (44.0--57.5)       59.0 (47.0--64.5)       0.042
  Menopause                  74/112 (66.1)          36/60 (60.0)            38/52 (73.1)            0.145
  Symptom duration, yr       10.0 (7.0--15.0)       10.0 (7.0--15.0)        12.0 (8.0--20.0)        0.073
  WBC, /mm^3^                4,370 (3,790--5,450)   4,065 (3,515--4,695)    4,660 (4,190--5,930)    4.63 × 10^--4^
  Neutrophils, /mm^3^        2,410 (1,740--3,179)   2,135 (1,563--2,857)    2,513 (1,967--3,924)    0.004
  Lymphocytes, /mm^3^        1,589 (1,246--1,901)   1,517 (1,176--1,711)    1,629 (1,295--2,049)    0.035
  Hemoglobin, g/dL           12.7 (12.0--13.4)      12.6 (11.9--13.4)       12.8 (12.1--13.4)       0.561
  Platelets, × 10^3^/mm^3^   220 (182--260)         209 (182--240)          228 (183--271)          0.121
  ESR, mm/hr                 21 (13--33)            21 (13--37)             20 (10--31)             0.316
  CRP, mg/dL                 0.07 (0.03--0.15)      0.06 (0.03--0.14)       0.07 (0.04--0.17)       0.181
  β2-MG, mg/dL               2.27 (1.84--2.64)      2.33 (1.87--2.55)       2.10 (1.77--2.74)       0.873
  IgG, g/dL                  1.71 (1.48--2.0)       1.72 (1.58--2.06)       1.65 (1.38--1.88)       0.061
  C3, mg/dL                  99.8 (86.3--111.3)     96.5 (86.3--107.5)      102.0 (86.4--25.2)      0.249
  C4, mg/dL                  21.2 (18.1--24.7)      19.5 (16.5--23.8)       22.2 (18.9--25.2)       0.027
  ESSPRI                     5.0 (3.7--6.7)         4.2 (3.0--5.7)          6.0 (4.5--7.3)          4.43 × 10^--4^
   ESSPRI ≥ 5                62 (53.9)              24 (38.7)               38 (61.3)               4.04 × 10^--4^
  ESSDAI                     2 (1--4)               2.5 (1--4)              1 (0--3)                0.011
   ESSDAI ≥ 5                19 (16.5)              12 (19.4)               7 (13.2)                0.376
  Current medications                                                                               
   Pilocarpine               59 (51.3)              25 (40.3)               34 (64.2)               0.011
   HCQ                       30 (26.1)              19 (30.6)               11 (20.8)               0.229
   PD                        24 (20.9)              10 (16.1)               14 (26.4)               0.175
    PD dose, mg/day          0.0 (0.0--0.0)         0.0 (0.0--0.0)          0.0 (0.0--2.5)          0.160
   Azathioprine              2 (1.7)                1 (1.6)                 1 (1.9)                 1.000
   Benzodiazepines           13 (11.3)              4 (6.5)                 9 (17.1)                0.086
   Hypnotics                 8 (6.1)                1 (1.6)                 7 (13.2)                0.023
   SSRI                      5 (4.3)                1 (1.6)                 4 (7.5)                 0.079
   SNRI                      3 (2.6)                1 (1.8)                 2 (3.8)                 0.594
   TCA                       3 (2.9)                0                       3 (5.7)                 0.095

Values are presented as number (%) or median (interquartile range). *p* values by the Mann-Whitney test, chi-square, or Fisher exact test.

WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; β2-MG, β2-microglobulin; IgG, immunoglobulin G; ESSPRI, European League Against Rheumatism (EULAR) Sjögren's syndrome (SS) Patient Reported Index; ESSDAI, EULAR SS Disease Activity Index; HCQ, hydroxychloroquine; PD, prednisolone; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant.

###### 

Patient-reported indices of the study subjects

  Variable                     Good sleeper (n = 62)   Poor sleeper (n = 53)   *p* value
  ---------------------------- ----------------------- ----------------------- -----------------
  EQ-5D score                  0.79 (0.70--1.00)       0.69 (0.62--0.75)       2.14 × 10^--4^
  Overall oral dryness VAS     46.0 (9.5--73.0)        60.0 (22.5--80.0)       0.128
  Nocturnal oral dryness VAS   20.0 (6.0--62.5)        40.0 (5.0--70.0)        0.757
  XI score                     34 (25--45)             41 (29--47)             0.098
  Overall eye dryness VAS      40.0 (8.0--69.3)        60.0 (22.2--80.0)       0.044
  Eyeball pain VAS             10.0 (0--40)            20.0 (2.0--70.0)        0.176
  OSDI score                   20.8 (10.4--31.3)       23.0 (13.5--41.7)       0.100
  ESS                          5.0 (2.9--5.7)          6.0 (5.0--7.3)          0.013
  Arthralgia VAS               10.0 (0.0--28.0)        40 (4.5--60.0)          0.005
  Myalgia VAS                  10.0 (0.0--29.0)        20.0 (1.0--60.0)        0.055
  Anxiety VAS                  2.5 (0.0--20.0)         10.0 (0.0--54.0)        0.037
  PGA VAS                      10.0 (2.8--40.0)        49.0 (20.0--70.0)       4.99 × 10^--4^
  PSQI score                   6.0 (3.0--7.3)          12.0 (10.0--15.0)       2.31 × 10^--20^
  FSS score                    2.56 (1.78--4.50)       4.56 (3.06--5.78)       2.64 × 10^--4^
   FSS score ≥ 4               19 (30.6)               30 (56.6)               0.005
  BDI-II score                 7.5 (4.0--12.3)         15.0 (7.5--21.5)        6.42 × 10^--5^
   BDI-II score ≥ 14           14 (22.6)               30 (56.6)               1.83 × 10^--4^

Values are presented as median (interquartile range) or number (%). *p* values by the Mann-Whitney or chi-square test.

EQ-5D, EuroQol 5-dimensional questionnaire; VAS, visual analogue scale; XI, xerostomia inventory; OSDI, Ocular Surface Disease Index; ESS, European League Against Rheumatism (EULAR) sicca score; PGA, patient global assessment for Sjögren's syndrome (SS); PSQI, Pittsburgh Sleep Quality Index; FSS, fatigue severity score; BDI, Beck Depression Inventory.

###### 

Correlations between Pittsburgh Sleep Quality Index and clinical variables

  Variable                   Spearman's coefficient   *p* value
  -------------------------- ------------------------ ----------------
  Age                        0.189                    0.043
  EQ-5D score                --0.418                  3.22 × 10^--6^
  Overall oral dryness VAS   0.214                    0.022
  XI score                   0.206                    0.027
  Overall eye dryness VAS    0.246                    0.009
  Eyeball pain VAS           0.192                    0.043
  OSDI score                 0.246                    0.008
  ESS                        0.288                    0.002
  Arthralgia VAS             0.312                    0.001
  Myalgia VAS                0.300                    0.001
  Anxiety VAS                0.278                    0.003
  PGA VAS                    0.366                    5.87 × 10^--5^
  FSS score                  0.402                    8.58 × 10^--6^
  BDI-II score               0.507                    7.34 × 10^--9^
  ESSPRI                     0.432                    1.44 × 10^--6^
  WBC counts                 0.236                    0.011
  ANC                        0.234                    0.012
  IgG levels                 --0.218                  0.019
  ESSDAI                     --0.259                  0.005

*p* values by the Spearman rank correlation test.

EQ-5D, EuroQol 5-dimensional questionnaire; VAS, visual analogue scale; XI, xerostomia inventory; OSDI, Ocular Surface Disease Index; ESS, European League Against Rheumatism (EULAR) sicca score; PGA, patient global assessment for Sjögren's syndrome (SS); FSS, fatigue severity score; BDI, Beck Depression Inventory; ESSPRI, EULAR SS Patient Reported Index; WBC, white blood cell; ANC, absolute neutrophil counts; IgG, immunoglobulin G; ESSDAI, EULAR SS Disease Activity Index.

###### 

Multivariate analysis by logistic regression

                                                                      β         SE      *p* value        OR (95% CI)
  ------------------------------------------------------------------- --------- ------- ---------------- ------------------------
  Poor sleep quality (PSQI ≥ 8.5) as a dependent variable                                                
   All subjects (n = 115)                                                                                
    Depression (BDI-II ≥ 14)                                          1.618     0.469   0.001            5.043 (2.012--12.640)
    Leukopenia                                                        --1.475   0.512   0.004            0.229 (0.084--0.625)
    Pilocarpine usage                                                 1.031     0.450   0.022            2.804 (1.160--6.779)
   Subjects without depression (n = 71)                                                                  
    Unsatisfactory symptom state (ESSPRI ≥ 5)                         1.505     0.586   0.010            4.505 (1.428--14.214)
    Ever-smoking                                                      1.988     0.976   0.042            7.298 (1.078--49.422)
   Subjects with depression (n = 44)                                                                     
    Leukopenia                                                        --3.068   1.111   0.006            0.047 (0.005--0.410)
    Age                                                               0.120     0.050   0.017            1.128 (1.021--1.245)
  Unsatisfactory symptom state (ESSPRI ≥ 5) as a dependent variable                                      
   Fatigue (FSS ≥ 4)                                                  2.393     0.542   1.00 × 10^--5^   10.942 (3.784--31.635)
   PGA, the 4th quartile                                              2.011     0.772   0.009            7.469 (1.645--33.915)
   Poor sleep quality                                                 1.162     0.513   0.023            3.197 (1.171--8.731)
   PD usage                                                           1.388     0.657   0.035            4.006 (1.105--14.526)

SE, standard error; OR, odds ratio; CI, confidence interval; PSQI, Pittsburgh Sleep Quality Index; BDI, Beck Depression Inventory; ESSPRI, European League Against Rheumatism (EULAR) Sjögren's syndrome (SS) Patient Reported Index; FSS, fatigue severity score; PGA, patient global assessment for SS; PD, prednisolone.

[^1]: These authors contributed equally to this work.
